A safety and efficacy trial of sorafenib (400 mg twice daily) in chemotherapy-naive patients with nonsquamous stage IIIB non-small-cell lung cancer has shown the treatment to be no better than the control regimen of gemcitabine (1,250 mg/m2 per day on days 1 and 8) and cisplatin (75 mg/m2 on day 1). The trial of 772 patients (385 in the sorafenib group and 387 in the control group), with similar demographic and baseline characteristics in both arms, demonstrated similar overall survival (12.4 months versus 12.5 months, hazard ratio 0.98, P = 0.401). Furthermore, sorafenib was associated with increased adverse events that included hand–foot skin reactions (8.6% versus 0.3%), fatigue (7.3% versus 3.6%) and hypertension (4.2% versus 1.8%).
ORIGINAL RESEARCH PAPER
Paz-Ares, L. G. et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J. Clin. Oncol. doi:10.1200/JCO.2011.39.7646
Rights and permissions
About this article
Cite this article
Sorafenib does not improve survival in nonsquamous NSCLC. Nat Rev Clin Oncol 9, 550 (2012). https://doi.org/10.1038/nrclinonc.2012.146
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.146